Mode
Text Size
Log in / Sign up

Enhanced CRE prevention program reduced CRE acquisition incidence in adults with risk factors compared to standard care.

Enhanced CRE prevention program reduced CRE acquisition incidence in adults with risk factors compar…
Photo by Marija Zaric / Unsplash
Key Takeaway
Consider enhanced CRE prevention programs in settings with high risk, though mortality benefits remain unproven.

This cluster-randomized controlled trial enrolled 363 adults with at least one CRE risk factor across six general medical wards at Siriraj Hospital. Participants were assigned to either an enhanced CRE prevention program or standard infection control care. The enhanced program included standard infection control care plus monthly staff education, real-time notifications of CRE acquisition, and contact-precaution reminders. The comparator was standard infection control care alone.

The primary outcome measured CRE acquisition incidence and CRE acquisition-free time. The cumulative incidence of CRE acquisition was 36.8% in the intervention group versus 46.6% in the comparator group with a P value of .06. The incidence rate per patient-day was 0.038 versus 0.058, which was significantly lower in the intervention group with a P value of .007. A post hoc analysis excluding acquisitions within 24 hours showed cumulative incidence of 25.7% versus 33.6% with a P value of .16.

The probability of remaining CRE-free had a hazard ratio of 0.72 with a 95% CI of 0.52-1.00 and a P value of .05 in the unadjusted analysis. When adjusted for prior antibiotic use, the hazard ratio was 0.75 with a 95% CI of 0.54-1.05 and a P value of .09. There were no differences in all-cause mortality or length of hospital stay as these outcomes were not reported with specific statistical values.

Safety and tolerability data were not reported. The study limitations note that larger studies are needed to explore benefits on morbidity and mortality. The practice relevance remains uncertain given the non-significant primary outcome and the need for further validation.

Study Details

Study typeRct
Sample sizen = 363
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Carbapenem-resistant Enterobacterales (CRE) colonization is a major risk factor for infection. Most infection prevention and control (IPC) strategies rely on private-room isolation, but evidence of their effectiveness in resource-limited settings is scarce. METHODS: From February to October 2021, we conducted a cluster-randomized controlled trial in 6 general medical wards at Siriraj Hospital, enrolling adults with ≥1 CRE risk factor. Wards were randomized to standard infection control care (sIC) or an enhanced CRE prevention program (eIC) comprising sIC plus monthly staff education, real-time notifications of CRE acquisition, and contact-precaution reminders. Active stool/rectal CRE surveillance was performed at enrollment and weekly. Primary outcomes were the CRE acquisition incidence and CRE acquisition-free time. RESULTS: A total of 363 patients were included: 174 in the intervention group (1684 patient-days) and 189 in the control group (1517 patient-days). The cumulative incidence of CRE acquisition was slightly lower in the intervention group (36.8% vs 46.6%; P = .06), with a significantly lower incidence rate per patient-day (0.038 vs 0.058; P = .007). In a post hoc analysis excluding acquisitions within 24 hours, the cumulative incidence was similar between groups (25.7% vs 33.6%; P = .16). The probability of remaining CRE-free showed an unadjusted hazard ratio (HR) of 0.72 [95% CI, 0.52-1.00; P = .05]. After adjusting for prior antibiotic use, the adjusted HR was 0.75 [95% CI, 0.54-1.05; P = .09]. There were no differences in all-cause mortality or length of hospital stay. CONCLUSIONS: Carbapenem-resistant Enterobacterales acquisition incidence was high in this setting. The enhanced CRE prevention program tended to reduce CRE acquisition and prolong CRE-free survival. Larger studies are needed to explore benefits on morbidity and mortality.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.